2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
327
Neoplasm Metastasis
40
Neoplasms
25
Advanced Breast Cancer
19
Ovarian Neoplasms
18
Carcinoma, Non-Small-Cell Lung
14
Endometrial Neoplasms
11
Prostatic Neoplasms
10
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Colorectal Neoplasms
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Multiple Endocrine Neoplasia Type 1
5
Carcinoma, Ovarian Epithelial
5
Breast Diseases
5
Neoplasms by Site
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Lobular
3
Breast Neoplasm Female
3
Uterine Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Interventions
pembrolizumab
7
Radiotherapy
3
Proton Therapy
3
Interleukin-2
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Rosuvastatin Calcium
2
Paclitaxel
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
Carboplatin
2
Blood Specimen Collection
2
toripalimab
1
tislelizumab
1
sotorasib
1
peposertib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
niraparib
1
neotil
1
necitumumab
1
mirdametinib
1
leronlimab
1
lenvatinib
1
atezolizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor, Adult
×
Fulvestrant
×
Clear all
NCT04092673
2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2
Unknown
30 enrolled